Magnasense Investor Relations Material
Latest events
Q2 2025
29 Aug, 2025
Q4 2024
5 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Magnasense
Access all reports
Magnasense, a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. Magnasense's main product is the Oncolynx®, a urine test to be used with treatment of colorectal cancer patients. The test measures the levels of the drug in the bloodstream. This helps physicians optimize the dosage to achieve effective and safe treatment of cancer with biological drugs. The company was incorporated in 2019 and is based in Lund, Sweden.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
MAGNA
Country
🇸🇪 Sweden